Rare primary liver cancers: An EASL position paper

Henning Wege; Claudia Campani; Ruben de Kleine; Tim Meyer; Jean-Charles Nault; Timothy M Pawlik; Maria Reig; Jens Ricke; Christine Sempoux; Guido Torzilli; Jessica Zucman-Rossi

doi:10.1016/j.jhep.2024.06.004

Rare primary liver cancers: An EASL position paper

J Hepatol. 2024 Jul 20:S0168-8278(24)02305-5. doi: 10.1016/j.jhep.2024.06.004. Online ahead of print.

Authors

Affiliations

¹ Cancer Center Esslingen, Klinikum Esslingen, D-73730 Esslingen, Germany; Department of Gastroenterology and Hepatology, University Medical Center Hamburg-Eppendorf, European Reference Network Hepatological Diseases (ERN RARE-LIVER), D-20246 Hamburg, Germany. Electronic address: [email protected].
² Department of Experimental and Clinical Medicine, Internal Medicine and Hepatology Unit, University of Firenze, Florence, Italy; Centre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Inserm, F-75006, Paris, France.
³ Department of Surgery, Section of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, ERN RARE-LIVER, University of Groningen, Groningen, The Netherlands.
⁴ Department of Oncology, Royal Free Hospital and UCL Cancer Institute, University College London, London UK.
⁵ Centre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Inserm, F-75006, Paris, France; Liver Unit, Avicenne Hospital, AP-HP, ERN RARE-LIVER, Paris-Seine-Saint-Denis University, Bobigny, France.
⁶ Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States.
⁷ Barcelona Clinic Liver Cancer (BCLC) group. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain; Liver Oncology Unit, Liver Unit, Hospital Clinic de Barcelona, ERN RARE-LIVER, Barcelona, Spain; Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. Barcelona University, Barcelona, Spain.
⁸ Department of Radiology, University Hospital, LMU Munich, Munich, Germany.
⁹ Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, CH-1011 Lausanne, Switzerland.
¹⁰ Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072, Milan, Italy; Division of Hepatobiliary & General Surgery, Department of Surgery - IRCCS, Humanitas Research Hospital, ERN RARE-LIVER, via Manzoni 56, Rozzano, 20089, Milan, Italy.
¹¹ Centre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Inserm, F-75006, Paris, France; Institut du Cancer Paris CARPEM, AP-HP, Department of Oncology, Hopital Européen Georges Pompidou, F-75015, Paris, France.

PMID: 39289102
DOI: 10.1016/j.jhep.2024.06.004

Abstract

In recent years, owing to advances in our understanding of hepatocarcinogenesis, rare primary liver cancers (PLCs), including combined hepatocellular-cholangiocarcinoma, fibrolamellar carcinoma, and hepatic epithelioid hemangioendothelioma have garnered increased attention. In this position paper, an international panel of experts representing oncology, hepatology, pathology, radiology, surgery, and molecular biology has summarised the available information and evidence on the pathogenesis, diagnosis, and treatment of rare PLCs. While clinical trials of systemic treatments are underway for some rare PLCs, it is evident that more research, involving national and international collaboration, is required.

Publication types

Practice Guideline